T-cell-rich large B-cell lymphoma in children and adolescents - A clinicopathologic report of six cases from the Children's Cancer Group Study CCG-5961
Ma. Lones et al., T-cell-rich large B-cell lymphoma in children and adolescents - A clinicopathologic report of six cases from the Children's Cancer Group Study CCG-5961, CANCER, 88(10), 2000, pp. 2378-2386
BACKGROUND. T-cell-rich large B-cell lymphoma (TCRLBCL) is a morphologic su
bset of diffuse large B-cell lymphoma that has been confused with Hodgkin d
isease and reactive lymphadenopathies. To the authors' knowledge the majori
ty of reports of TCRLBCL are from adults, and it is not widely recognized a
s occurring in the pediatric population. The current study reports a cohort
of six cases of TCRLBCL from the Children's Cancer Group CCG-5961 study.
METHODS. Biopsies from patients entered on CCG-5961 were submitted for cent
ral pathology review and immunophenotyping. Six cases of TCRLBCL were ident
ified and correlated with clinical characteristics.
RESULTS. Of 86 cases centrally reviewed to date on CCG-5961, 20 (23%) were
diagnosed as diffuse large B-cell lymphomas. Of these, 6 cases(7% of total
cases and 30% of large B-cell cases) were TCRLBCL, based on a diffuse growt
h pattern with a minor population of neoplastic large B cells and an associ
ated extensive reactive T-cell infiltrate. All patients with TCRLBCL were m
ales ages 12-16 years. Three patients with TCRLBCL had advanced stage disea
se. No bone marrow or central nervous system involvement was detected in an
y case.
CONCLUSIONS. TCRLBCL is a morphologic subtype of diffuse large B-cell lymph
oma that may be difficult to recognize due to the extensive infiltrate of r
eactive T cells. This entity is not well recognized in pediatric patients,
but in the current study represented 7% of all cases and 30% of large B-cel
l lymphomas received for central review from the ongoing CCG-5961 protocol.
Because TCRLBCL may be confused with Hodgkin disease and reactive lymphade
nopathies, it is essential that this entity be recognized in the pediatric
age group. Cancer 2000;88:2378-86. (C) 2000 American Cancer Society.